Soligenix Platform Enables Rapid Bundibugyo Vaccine with Two-Year Thermal Stability and 100% NHP Protection
SNGX•Soligenix's ThermoVax platform has demonstrated at least two-year stability at 40°C and 100% non-human primate protection for multivalent filovirus subunit vaccines, and recent preclinical work shows compatibility with Bundibugyo virus antigen enabling rapid development of a thermostable vaccine. The Congo Bundibugyo outbreak has yielded 246 suspected cases and 80 deaths.
1. ThermoVax Platform Data
Soligenix's proprietary ThermoVax platform has produced lyophilized protein subunit vaccines with demonstrated stability at 40°C for at least two years and generated robust immune responses in mice and 100% protection against lethal filovirus challenge in non-human primates.
2. Bundibugyo Vaccine Development
Preclinical work in collaboration with Dr. Axel Lehrer has shown that the key glycoprotein antigen for Bundibugyo virus is compatible with the ThermoVax platform, enabling formulation of a single-vial thermostable subunit vaccine requiring only ambient shipping and reconstitution with sterile water prior to use.
3. Outbreak Context and Commercial Outlook
The ongoing Bundibugyo virus outbreak in the Democratic Republic of Congo has recorded 246 suspected cases and 80 deaths as of May 15, 2026, highlighting the need for rapid vaccine deployment; orphan drug designations for related filovirus vaccines also position Soligenix to leverage regulatory incentives and government funding for further development.
